Form 4 for RIGL RIGEL PHARMACEUTICALS INC
Accepted 2025-01-31 00:00:00 ET · period of report 2025-01-29 · accession 0000905148-25-000298 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-31 | 2025-01-29 | RIGL | Furey Raymond J. | EVP, GC, CCO, Corp Sec | A - Grant | $0.00 | +19.7K | 41.6K | +90% | $0 |
| D | 2025-01-31 | 2025-01-29 | RIGL | Furey Raymond J. | EVP, GC, CCO, Corp Sec | A - Grant | $0.00 | +14.8K | 14.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-29 | A | A | 19,717 | $0.00 | 41,617 | D | — | — | (F1) The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026. (F3) Includes 500 shares acquired under the Issuer's stock purchase plan. (F2) This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2025-01-29 | A | A | 14,788 | $0.00 | 14,788 | D | $22.49 · — to 2035-01-29 | 14,788 Common Stock | (F4) The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period. |